PRESS RELEASE: CARB-X Awards $1.8 Million to Visby Medical for Development of Rapid Gonorrhea Diagnostic
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded Visby…
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded Visby…
HelixBind, Inc., a developer of in-vitro diagnostic products for the characterization of invasive in…
T2 Biosystems announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA…
Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International,…
The World Health Organization and the Medicines Patent Pool on Wednesday announced a license agreeme…
Qiagen has announced the launch of two syndromic testing panels for its QIAstat-Dx instruments in In…
A team of researchers from Tohoku University and Okinawa Institute of Science and Technology (OIST) …